Abstract
High grade gliomas (HGGs) are the most frequent and highly invasive type of brain tumors, which arise from glial cells. Among HGGs, glioblastoma multiforme (GBM) is the commonest and deadliest tumor type. Standard HGG therapy that involves tumor resection followed by concomitant treatment with radiation exposure and temozolomide (TMZ) cannot prevent recurrent tumor. The median survival of treated patients after surgery does not exceed 1.5 years. Vaccination with autologous dendritic cells (DCs) pulsed with tumor-specific peptides, antigens, or lysates is considered as a promising option to induce a potent anti-tumor immune response and cytotoxicity against GBM cells. However, since the tumor microenvironment is highly immunosuppressive and immunotolerant, specialized approaches should be applied to protect DC transplants against tumor-induced functional impairment and inhibition. So far, many phase I-III clinical trials utilizing DC vaccines for HGG treatment were completed or are underway. In summary, DC vaccination was safe and well tolerated by patients. DC-induced anti-tumor immune responses correlated with prolonged overall and progression- free survival. Combination of DC therapy with other interventional strategies (i.e., radiotherapy, chemotherapy, antibodies, etc.) and multimodal approaches should improve HGG treatment outcomes. In this review, we consider strategies that provide an option to override the immune inhibitory tumor microenvironment and boost DC vaccine-based antitumor immune response.
Keywords: Glioblastoma, dendritic cell vaccine, immune therapy, antigenic peptide, immune suppression, dendritic cell maturation.
Current Pharmaceutical Design
Title:Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Volume: 22 Issue: 37
Author(s): Dimitry A. Chistiakov, Ivan V. Chekhonin, Olga I. Gurina, Yuri V. Bobryshev and Vladimir P. Chekhonin
Affiliation:
Keywords: Glioblastoma, dendritic cell vaccine, immune therapy, antigenic peptide, immune suppression, dendritic cell maturation.
Abstract: High grade gliomas (HGGs) are the most frequent and highly invasive type of brain tumors, which arise from glial cells. Among HGGs, glioblastoma multiforme (GBM) is the commonest and deadliest tumor type. Standard HGG therapy that involves tumor resection followed by concomitant treatment with radiation exposure and temozolomide (TMZ) cannot prevent recurrent tumor. The median survival of treated patients after surgery does not exceed 1.5 years. Vaccination with autologous dendritic cells (DCs) pulsed with tumor-specific peptides, antigens, or lysates is considered as a promising option to induce a potent anti-tumor immune response and cytotoxicity against GBM cells. However, since the tumor microenvironment is highly immunosuppressive and immunotolerant, specialized approaches should be applied to protect DC transplants against tumor-induced functional impairment and inhibition. So far, many phase I-III clinical trials utilizing DC vaccines for HGG treatment were completed or are underway. In summary, DC vaccination was safe and well tolerated by patients. DC-induced anti-tumor immune responses correlated with prolonged overall and progression- free survival. Combination of DC therapy with other interventional strategies (i.e., radiotherapy, chemotherapy, antibodies, etc.) and multimodal approaches should improve HGG treatment outcomes. In this review, we consider strategies that provide an option to override the immune inhibitory tumor microenvironment and boost DC vaccine-based antitumor immune response.
Export Options
About this article
Cite this article as:
Chistiakov A. Dimitry, Chekhonin V. Ivan, Gurina I. Olga, Bobryshev V. Yuri and Chekhonin P. Vladimir, Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas, Current Pharmaceutical Design 2016; 22 (37) . https://dx.doi.org/10.2174/1381612822666160719110618
DOI https://dx.doi.org/10.2174/1381612822666160719110618 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Role of Natural Killer Cell Activity in the Pathogenesis of Endometriosis
Current Medicinal Chemistry Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis
Current Pharmaceutical Design Targeting p53 in Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Identification of 2-Fluoropalmitic Acid as a Potential Therapeutic Agent Against Glioblastoma
Current Pharmaceutical Design Stem Cell-Like Brain Cancer Cells
Current Cancer Therapy Reviews Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Perspective of MiRNAs in Clinical Glioblastoma Research
Current Signal Transduction Therapy P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Using the Concept of Chous Pseudo Amino Acid Composition to Predict Enzyme Family Classes: An Approach with Support Vector Machine Based on Discrete Wavelet Transform
Protein & Peptide Letters Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery p53: A Guide to Apoptosis
Current Cancer Drug Targets